In Cox multivariate regression analyses adjusting for tumour differentiation grade, KPS and type of 1st-line chemotherapy (where appropriate), we identified high TPX2 expression as independent negative prognostic tissue biomarker for PFS and OS in the 1st-line gemcitabine-treated patient subgroup (P < 0.001 each, Supplementary Table S6) but not in the non-gemcitabine 1st-line treatment subgroup as expected. The gene discussed is TPX2; the disease is neoplasm.